E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Histopathologically confirmed renal cell carcinoma with metastases |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 8.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10038415 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this protocol is to provide access to SU011248 treatment for patients with metastatic RCC given all of the following conditions are met: a) patients are ineligible for participation in ongoing SU011248 clinical studies (if any Phase 1, 2 or 3 SU011248 protocols for patients having RCC are open to enrollment at the institution), and b) patients have cytokine-refractory RCC, and c) patients have the potential to derive clinical benefit from treatment with SU011248 based on the judgment of the investigator.
|
|
E.2.2 | Secondary objectives of the trial |
Other objectives include the assessment of: • Safety and tolerability profile of SU011248 • The antitumor efficacy of single-agent SU011248 given orally at a dose of 50 mg in patients with cytokine-refractory metastatic RCC
|
|
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
Patients must meet all of the following inclusion criteria to be eligible for enrollment into the trial: 1. Histopathologically confirmed renal cell carcinoma with metastases. 2. Renal cell carcinoma that is not amenable to standard therapy with curative intent. 3. Have cytokine-refractory disease 4. Must be ineligible for participation in ongoing SU011248 clinical studies (if any Phase 1, 2 or 3 SU011248 protocols for patients having RCC are open to enrollment at the institution). 5. Judged by the treating physician to have the potential to derive clinical benefit from SU011248 treatment. 6. Male or female, 18 years of age or older. 7. Resolution of all acute toxic effects of prior systemic therapy, radiotherapy or surgical procedure to NCI CTCAE Version 3.0 grade less/equal to 1. 8. Adequate organ function as defined by the following criteria: • Total serum bilirubin less/equal to 2 x ULN (patients with Gilbert’s disease exempt) • Serum transaminases <5 x ULN • Serum creatinine less/equal 2 x ULN • Absolute neutrophil count (ANC) major/equal to 1000/mL without growth factor support • Platelets major/equal to 75,000/mL • Hemoglobin major/equal to 8.0 g/dL 9. Signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all the pertinent aspects of the trial prior to enrollment. 10. Willingness and ability to comply with scheduled visits, treatment plans and laboratory tests and other study procedures.
|
|
E.4 | Principal exclusion criteria |
1. Current treatment in another therapeutic clinical trial 2. Congestive heart failure, myocardial infarction or coronary artery bypass graft in the previous six months, ongoing severe or unstable angina or any unstable arrhythmia requiring medication 3. Previous treatment on a SU011248 trial 4. Pregnancy or breastfeeding. Patients must be surgically sterile or be postmenopausal, or must agree to use effective contraception during the period of therapy. The definition of effective contraception will be based on the judgment of the principal investigator or a designated associate. Male patients must be surgically sterile or agree to use effective contraception. 5. Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that would impart, in the judgment of the investigator, excess risk associated with study participation or study drug administration, or which, in the judgment of the investigator, would make the patient inappropriate for entry into this study
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary objective is to provide access to SU011248 treatment for patients with cytokine-refractory metastatic RCC according to conditions described in the protocol without formal hypothesis testing. In addition, the following clinical endpoints will be evaluated. • Safety profile of SU011248 • Overall survival (OS) • Time-to-progression (TTP) • Progression-free survival (PFS) • Objective response rate (ORR) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Information not present in EudraCT |
E.6.2 | Prophylaxis | Information not present in EudraCT |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Information not present in EudraCT |
E.6.6 | Pharmacokinetic | Information not present in EudraCT |
E.6.7 | Pharmacodynamic | Information not present in EudraCT |
E.6.8 | Bioequivalence | Information not present in EudraCT |
E.6.9 | Dose response | Information not present in EudraCT |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | Information not present in EudraCT |
E.6.12 | Pharmacoeconomic | Information not present in EudraCT |
E.6.13 | Others | Information not present in EudraCT |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Information not present in EudraCT |
E.7.1.1 | First administration to humans | Information not present in EudraCT |
E.7.1.2 | Bioequivalence study | Information not present in EudraCT |
E.7.1.3 | Other | Information not present in EudraCT |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Information not present in EudraCT |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | Information not present in EudraCT |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Information not present in EudraCT |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Patients may continue to access SU011248 on this protocol as long as there is evidence of disease control in the judgment of the investigator. Patients on study at the time of marketing authorization will continue to receive SU011248 as long as they are receiving clinical benefit in the judgment of the investigator. Survival will be monitored on all patients for up to 2 years from the date of first dose of SU011248. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |